Orthofix Medical (OFIX) Stock Overview
Operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OFIX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Orthofix Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.69 |
| 52 Week High | US$16.99 |
| 52 Week Low | US$9.13 |
| Beta | 0.71 |
| 1 Month Change | -16.82% |
| 3 Month Change | -21.67% |
| 1 Year Change | -12.31% |
| 3 Year Change | -48.65% |
| 5 Year Change | -77.19% |
| Change since IPO | -7.71% |
Recent News & Updates
Narrative Update • Jun 03
OFIX: CMS Reimbursement Reset And 2026 Guidance Will Support Multi Year Repricing
Orthofix Medical's updated fair value estimate has been reduced to $15.00 from $17.25, as analysts factor in lower projected revenue growth, a slightly higher discount rate, and Street research highlighting the impact of recent CMS reimbursement changes on the company's non-invasive bone growth stimulator portfolio. Analyst Commentary Street research on Orthofix Medical reflects a mix of cautious and constructive views following the recent CMS reimbursement updates and the company's revised long-term outlook.Narrative Update • May 16
OFIX: Later Margin Timeline And 2026 Outlook Will Support Multi Year Repricing
Narrative Update: Orthofix Medical Analysts have trimmed their average price targets for Orthofix Medical by a few dollars into a range of about $17 to $20 after revising models for Q4 results and updated margin timelines. This aligns with a fair value estimate of $17.25 and modest adjustments to growth, discount rate, margin assumptions and future P/E expectations.Analysis Article • May 08
US$17.25: That's What Analysts Think Orthofix Medical Inc. (NASDAQ:OFIX) Is Worth After Its Latest Results
It's been a good week for Orthofix Medical Inc. ( NASDAQ:OFIX ) shareholders, because the company has just released its...Recent updates
Narrative Update • Jun 03
OFIX: CMS Reimbursement Reset And 2026 Guidance Will Support Multi Year Repricing
Orthofix Medical's updated fair value estimate has been reduced to $15.00 from $17.25, as analysts factor in lower projected revenue growth, a slightly higher discount rate, and Street research highlighting the impact of recent CMS reimbursement changes on the company's non-invasive bone growth stimulator portfolio. Analyst Commentary Street research on Orthofix Medical reflects a mix of cautious and constructive views following the recent CMS reimbursement updates and the company's revised long-term outlook.Narrative Update • May 16
OFIX: Later Margin Timeline And 2026 Outlook Will Support Multi Year Repricing
Narrative Update: Orthofix Medical Analysts have trimmed their average price targets for Orthofix Medical by a few dollars into a range of about $17 to $20 after revising models for Q4 results and updated margin timelines. This aligns with a fair value estimate of $17.25 and modest adjustments to growth, discount rate, margin assumptions and future P/E expectations.Analysis Article • May 08
US$17.25: That's What Analysts Think Orthofix Medical Inc. (NASDAQ:OFIX) Is Worth After Its Latest Results
It's been a good week for Orthofix Medical Inc. ( NASDAQ:OFIX ) shareholders, because the company has just released its...Narrative Update • Apr 24
OFIX: Later Margin Timeline And 2026 Guidance Will Support Multi Year Repricing
Narrative Update on Orthofix Medical The analyst price target for Orthofix Medical edges down to $17.25, with analysts pointing to refreshed Q4 based models, updated 2026 guidance, and a longer adjusted EBITDA margin timeline as key reasons for the adjustment. Analyst Commentary Recent Street research on Orthofix Medical shows a cluster of target price reductions, driven mainly by refreshed Q4 models, updated 2026 guidance, and a longer path to the company’s adjusted EBITDA margin goals.
Narrative Update • Apr 10
OFIX: Extended EBITDA Timeline Will Support 2028 Profitability And Margin Reassessment
Orthofix Medical's updated analyst price targets cluster in the mid to high teens, with several firms trimming their views to a range of about $17 to $20 as analysts refresh models for recent Q4 results, revised 2026 guidance, and a longer timeline for margin expansion. Analyst Commentary Recent Street research on Orthofix reflects a more cautious tone, even as analysts refresh models following Q4 results and updated 2026 guidance.Narrative Update • Mar 27
OFIX: Longer EBITDA Timeline Will Set Up 2028 Profitability Reassessment
Orthofix Medical’s latest narrative update keeps fair value unchanged at $14.00, as analysts temper price targets to a $17 to $20 range after revising models around Q4 results, updated 2026 guidance, and a longer timeline to reach adjusted EBITDA margin goals. Analyst Commentary Recent research updates show that bearish analysts are trimming expectations for Orthofix Medical, even as they maintain generally constructive views on the business.Narrative Update • Mar 13
OFIX: Later Margin Timeline And 2026 Outlook Will Support Multi Year Repricing
Analysts have trimmed their fair value estimate for Orthofix Medical to $17.25 from $19.25, reflecting recent reductions in Street price targets as models are refreshed following Q4 results and updated long term guidance. Analyst Commentary Street research on Orthofix Medical has recently focused on recalibrating valuation targets and timing assumptions following Q4 results and updated long term guidance.Narrative Update • Feb 26
OFIX: Later Margin Timeline Will Support Bullish Multi Year Earnings Repricing
Analysts have lowered their price target on Orthofix Medical from $22.55 to $19.25. This change reflects updated views on the timing of margin improvement and valuation metrics, following recent research that indicates a later adjusted EBITDA margin target and a more neutral stance on the shares.Narrative Update • Feb 11
OFIX: Neutral Outlook Will Weigh Execution Risks Against Margin And Multiple Assumptions
Analysts have maintained their $14.00 price target on Orthofix Medical, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are consistent with a recently initiated neutral view on the stock. Analyst Commentary Bearish analysts are broadly signaling a wait and see stance on Orthofix Medical, with the neutral initiation and maintained $14.00 price target reflecting a more cautious setup rather than a clear bullish call.Narrative Update • Jan 28
OFIX: Neutral Spine Platform Outlook Will Balance Execution Risk And Margin Potential
Analysts have trimmed their price target on Orthofix Medical to US$14.00 from US$18.00. This reflects updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations following recent research, including a neutral initiation at TD Cowen.Narrative Update • Jan 07
OFIX: Spine Platform Execution Will Support Future Margin Expansion And Earnings Power
Analysts have adjusted their outlook on Orthofix Medical, highlighting a Street price target of US$22 and citing expectations for "profitable growth at an attractive valuation" as investors wait for longer term benefits from the 7D FLASH spine platform. Analyst Commentary The current Street view on Orthofix Medical centers on a US$22 price target that reflects confidence in the company’s ability to deliver profitable growth while investors wait for potential benefits tied to the 7D FLASH spine platform and broader spine industry trends.Narrative Update • Dec 14
OFIX: Spine Technology Tailwinds Will Support Margin Expansion And Earnings Power
Analysts have raised their fair value estimate for Orthofix Medical to $18.00 from $17.00, citing expectations for slightly faster revenue growth, improved profit margins, and a still attractive valuation supported by recent Buy-rated Street research. Analyst Commentary Recent Street commentary has highlighted a constructive long term outlook for Orthofix Medical, with the latest research emphasizing profitable growth potential supported by emerging technology tailwinds in the spine segment.Analysis Article • Nov 07
Here's What Analysts Are Forecasting For Orthofix Medical Inc. (NASDAQ:OFIX) After Its Third-Quarter Results
Last week, you might have seen that Orthofix Medical Inc. ( NASDAQ:OFIX ) released its third-quarter result to the...Seeking Alpha • Aug 07
Orthofix Medical: Compelling Valuation Supported By Insider Purchases
Summary We increased our Orthofix Medical position after a sharp sell-off, viewing the valuation as compelling, especially with insider and major shareholder buying. Orthofix’s integration of Seaspine is nearly complete, financials are strong, and management reaffirmed positive free cash flow and EBITDA margin improvement targets for 2025-2027. Recent revenue guidance cut was due to one-time factors, not long-term weakness; new product launches and FDA clearances support future growth across all segments. At just 6.4x 2025 EBITDA, OFIX trades at a deep discount to peers; our $18.50 price target offers 65.9% upside, with further potential if margin goals are met. Read the full article on Seeking Alpha
New Narrative • Mar 26
7D FLASH And New Products Will Revitalize US Orthopedics Market
Orthofix's investments in enabling technologies and innovative products are set to enhance market penetration and competitive advantage, driving revenue growth.Shareholder Returns
| OFIX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.5% | 2.6% | -2.5% |
| 1Y | -12.3% | -20.0% | 22.7% |
Return vs Industry: OFIX exceeded the US Medical Equipment industry which returned -20% over the past year.
Return vs Market: OFIX underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| OFIX volatility | |
|---|---|
| OFIX Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OFIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OFIX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,605 | Massimo Calafiore | orthofix.com |
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions.
Orthofix Medical Inc. Fundamentals Summary
| OFIX fundamental statistics | |
|---|---|
| Market cap | US$415.94m |
| Earnings (TTM) | -US$60.01m |
| Revenue (TTM) | US$825.37m |
0.5x
P/S Ratio-6.5x
P/E RatioIs OFIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OFIX income statement (TTM) | |
|---|---|
| Revenue | US$825.37m |
| Cost of Revenue | US$239.27m |
| Gross Profit | US$586.10m |
| Other Expenses | US$646.11m |
| Earnings | -US$60.01m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.48 |
| Gross Margin | 71.01% |
| Net Profit Margin | -7.27% |
| Debt/Equity Ratio | 50.9% |
How did OFIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 21:46 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orthofix Medical Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Spencer Nam | Brean Capital Historical (Janney Montgomery) |
| Caitlin Cronin | Canaccord Genuity |